Related Experiment Video
Updated: Jul 3, 2025

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
New evidence for flexible psilocybin dosing in patients with treatment-resistant depression
Scott T Aaronson1, Zofia Kozak2
1Institute for Advanced Diagnosis and Therapeutics, Sheppard Pratt Hospital System, Baltimore, MD, USA; University of Maryland School of Medicine, Department of Psychiatry, Baltimore, MD, USA.
Abstract:
Psilocybin has demonstrated efficacy for treating depression; however, psychiatrically complex patients have been excluded from trials. A recent clinical trial by Rosenblat at al.1 demonstrates feasibility of a flexible dosing schedule of psilocybin in individuals with severely treatment-resistant depression (TRD), including those with co-morbid conditions or bipolar II disorder (BPII), potentially expanding the current treatment paradigm.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Electroconvulsive Therapy
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

